Pfizer has joined forces with Novartis to bring together the therapies they have been working on independently, to treat non-alcoholic steatohepatitis (NASH).
Takeda has proposed selling off a Shire treatment for inflammatory bowel disease when the companies merge next year, to avoid an overlap with its own drug.
Within the life science industry, uptake of blockchain is in the early stages, but with investment levels in distributed ledger technology (DLT) on the rise, then it would appear that momentum is b
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
